Abstract
Summary
The global Phenylketonuria Therapeutic market size is projected to grow from US$ 978.3 million in 2022 to US$ 1779.3 million in 2029; it is expected to grow at a CAGR of 8.9% from 2023 to 2029.
United States market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phenylketonuria Therapeutic players cover Biomarin, Mead Johnson, Abbott, Nutricia, Dr. Schär, Vitaflo, Cambrooke, PKU Perspectives and Firstplay Dietary, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
LPI (LP Information)' newest research report, the “Phenylketonuria Therapeutic Industry Forecast” looks at past sales and reviews total world Phenylketonuria Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Phenylketonuria Therapeutic sales for 2023 through 2029. With Phenylketonuria Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phenylketonuria Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Phenylketonuria Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phenylketonuria Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phenylketonuria Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phenylketonuria Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phenylketonuria Therapeutic.
This report presents a comprehensive overview, market shares, and growth opportunities of Phenylketonuria Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Medications
Supplements
Segmentation by application
Household
Hospital
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
United States market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phenylketonuria Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phenylketonuria Therapeutic players cover Biomarin, Mead Johnson, Abbott, Nutricia, Dr. Schär, Vitaflo, Cambrooke, PKU Perspectives and Firstplay Dietary, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
LPI (LP Information)' newest research report, the “Phenylketonuria Therapeutic Industry Forecast” looks at past sales and reviews total world Phenylketonuria Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Phenylketonuria Therapeutic sales for 2023 through 2029. With Phenylketonuria Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phenylketonuria Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Phenylketonuria Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phenylketonuria Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phenylketonuria Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phenylketonuria Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phenylketonuria Therapeutic.
This report presents a comprehensive overview, market shares, and growth opportunities of Phenylketonuria Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Medications
Supplements
Segmentation by application
Household
Hospital
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Phenylketonuria Therapeutic Market Size 2018-2029
2.1.2 Phenylketonuria Therapeutic Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Phenylketonuria Therapeutic Segment by Type
2.2.1 Medications
2.2.2 Supplements
2.3 Phenylketonuria Therapeutic Market Size by Type
2.3.1 Phenylketonuria Therapeutic Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Phenylketonuria Therapeutic Market Size Market Share by Type (2018-2023)
2.4 Phenylketonuria Therapeutic Segment by Application
2.4.1 Household
2.4.2 Hospital
2.5 Phenylketonuria Therapeutic Market Size by Application
2.5.1 Phenylketonuria Therapeutic Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Phenylketonuria Therapeutic Market Size Market Share by Application (2018-2023)
3 Phenylketonuria Therapeutic Market Size by Player
3.1 Phenylketonuria Therapeutic Market Size Market Share by Players
3.1.1 Global Phenylketonuria Therapeutic Revenue by Players (2018-2023)
3.1.2 Global Phenylketonuria Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Phenylketonuria Therapeutic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Phenylketonuria Therapeutic by Regions
4.1 Phenylketonuria Therapeutic Market Size by Regions (2018-2023)
4.2 Americas Phenylketonuria Therapeutic Market Size Growth (2018-2023)
4.3 APAC Phenylketonuria Therapeutic Market Size Growth (2018-2023)
4.4 Europe Phenylketonuria Therapeutic Market Size Growth (2018-2023)
4.5 Middle East & Africa Phenylketonuria Therapeutic Market Size Growth (2018-2023)
5 Americas
5.1 Americas Phenylketonuria Therapeutic Market Size by Country (2018-2023)
5.2 Americas Phenylketonuria Therapeutic Market Size by Type (2018-2023)
5.3 Americas Phenylketonuria Therapeutic Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Phenylketonuria Therapeutic Market Size by Region (2018-2023)
6.2 APAC Phenylketonuria Therapeutic Market Size by Type (2018-2023)
6.3 APAC Phenylketonuria Therapeutic Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Phenylketonuria Therapeutic by Country (2018-2023)
7.2 Europe Phenylketonuria Therapeutic Market Size by Type (2018-2023)
7.3 Europe Phenylketonuria Therapeutic Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Phenylketonuria Therapeutic by Region (2018-2023)
8.2 Middle East & Africa Phenylketonuria Therapeutic Market Size by Type (2018-2023)
8.3 Middle East & Africa Phenylketonuria Therapeutic Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Phenylketonuria Therapeutic Market Forecast
10.1 Global Phenylketonuria Therapeutic Forecast by Regions (2024-2029)
10.1.1 Global Phenylketonuria Therapeutic Forecast by Regions (2024-2029)
10.1.2 Americas Phenylketonuria Therapeutic Forecast
10.1.3 APAC Phenylketonuria Therapeutic Forecast
10.1.4 Europe Phenylketonuria Therapeutic Forecast
10.1.5 Middle East & Africa Phenylketonuria Therapeutic Forecast
10.2 Americas Phenylketonuria Therapeutic Forecast by Country (2024-2029)
10.2.1 United States Phenylketonuria Therapeutic Market Forecast
10.2.2 Canada Phenylketonuria Therapeutic Market Forecast
10.2.3 Mexico Phenylketonuria Therapeutic Market Forecast
10.2.4 Brazil Phenylketonuria Therapeutic Market Forecast
10.3 APAC Phenylketonuria Therapeutic Forecast by Region (2024-2029)
10.3.1 China Phenylketonuria Therapeutic Market Forecast
10.3.2 Japan Phenylketonuria Therapeutic Market Forecast
10.3.3 Korea Phenylketonuria Therapeutic Market Forecast
10.3.4 Southeast Asia Phenylketonuria Therapeutic Market Forecast
10.3.5 India Phenylketonuria Therapeutic Market Forecast
10.3.6 Australia Phenylketonuria Therapeutic Market Forecast
10.4 Europe Phenylketonuria Therapeutic Forecast by Country (2024-2029)
10.4.1 Germany Phenylketonuria Therapeutic Market Forecast
10.4.2 France Phenylketonuria Therapeutic Market Forecast
10.4.3 UK Phenylketonuria Therapeutic Market Forecast
10.4.4 Italy Phenylketonuria Therapeutic Market Forecast
10.4.5 Russia Phenylketonuria Therapeutic Market Forecast
10.5 Middle East & Africa Phenylketonuria Therapeutic Forecast by Region (2024-2029)
10.5.1 Egypt Phenylketonuria Therapeutic Market Forecast
10.5.2 South Africa Phenylketonuria Therapeutic Market Forecast
10.5.3 Israel Phenylketonuria Therapeutic Market Forecast
10.5.4 Turkey Phenylketonuria Therapeutic Market Forecast
10.5.5 GCC Countries Phenylketonuria Therapeutic Market Forecast
10.6 Global Phenylketonuria Therapeutic Forecast by Type (2024-2029)
10.7 Global Phenylketonuria Therapeutic Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Biomarin
11.1.1 Biomarin Company Information
11.1.2 Biomarin Phenylketonuria Therapeutic Product Offered
11.1.3 Biomarin Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Biomarin Main Business Overview
11.1.5 Biomarin Latest Developments
11.2 Mead Johnson
11.2.1 Mead Johnson Company Information
11.2.2 Mead Johnson Phenylketonuria Therapeutic Product Offered
11.2.3 Mead Johnson Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Mead Johnson Main Business Overview
11.2.5 Mead Johnson Latest Developments
11.3 Abbott
11.3.1 Abbott Company Information
11.3.2 Abbott Phenylketonuria Therapeutic Product Offered
11.3.3 Abbott Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Abbott Main Business Overview
11.3.5 Abbott Latest Developments
11.4 Nutricia
11.4.1 Nutricia Company Information
11.4.2 Nutricia Phenylketonuria Therapeutic Product Offered
11.4.3 Nutricia Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Nutricia Main Business Overview
11.4.5 Nutricia Latest Developments
11.5 Dr. Schär
11.5.1 Dr. Schär Company Information
11.5.2 Dr. Schär Phenylketonuria Therapeutic Product Offered
11.5.3 Dr. Schär Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Dr. Schär Main Business Overview
11.5.5 Dr. Schär Latest Developments
11.6 Vitaflo
11.6.1 Vitaflo Company Information
11.6.2 Vitaflo Phenylketonuria Therapeutic Product Offered
11.6.3 Vitaflo Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Vitaflo Main Business Overview
11.6.5 Vitaflo Latest Developments
11.7 Cambrooke
11.7.1 Cambrooke Company Information
11.7.2 Cambrooke Phenylketonuria Therapeutic Product Offered
11.7.3 Cambrooke Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Cambrooke Main Business Overview
11.7.5 Cambrooke Latest Developments
11.8 PKU Perspectives
11.8.1 PKU Perspectives Company Information
11.8.2 PKU Perspectives Phenylketonuria Therapeutic Product Offered
11.8.3 PKU Perspectives Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 PKU Perspectives Main Business Overview
11.8.5 PKU Perspectives Latest Developments
11.9 Firstplay Dietary
11.9.1 Firstplay Dietary Company Information
11.9.2 Firstplay Dietary Phenylketonuria Therapeutic Product Offered
11.9.3 Firstplay Dietary Phenylketonuria Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Firstplay Dietary Main Business Overview
11.9.5 Firstplay Dietary Latest Developments
12 Research Findings and Conclusion